Compassionate mesenchymal stem cell treatment in a severe COVID-19 patient: a case report
Dragan Primorac, Sanda Stojanović, Stipić, Marko Strbad, Lenart Girandon, Ariana Barlič, Mileva Frankić, Ivo Ivić, Daniela Marasović, Krstulović, Irena Jukić, Beata Halassy, Ana Hečimović, Vid Matišić, Vilim Molnar
Abstract
COVID-19 presentations range from cold-like symptoms to severe symptoms with the development of acute respiratory distress syndrome (ARDS). We report on a severe COVID-19 patient who was mechanically ventilated and who developed ARDS and bacterial infection. Because of rapid clinical deterioration and the exhaustion of other treatment options, the family and attending physicians requested a compassionate use of adult allogeneic bone marrow-derived mesenchymal stem cells (MSC) in addition to commonly used immunosuppressive, antiviral, and supportive therapy. The clinical course is discussed thoroughly, with a special emphasis on the safety and effect of MSC therapy. Compassionate MSC treatment, given in three rounds, affected ARDS regression. The patient was discharged from the intensive care unit after 31 days and from hospital after 49 days in a good general condition. MSC treatment was not associated with any side effects and was well tolerated in a three-week period; therefore, it should be studied in larger trials and considered for compassionate use.